Design of a pharmaceutical composition with a low-dose statin and a high lipid-lowering activity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Due to the risk of side effects with prolonged use of statins, one of the urgent tasks of pharmacy and pharmacology is to design a drug composition with low-dose statins while maintaining their effect. This problem can be solved with the combined use of statins and antioxidants, which enhances the anti-atherogenic effect of atorvastatin and reduces the serum level of atherogenic lipoproteins. Objective: to investigate the lipid-lowering effect of a combination of atorvastatin and the antioxidant ethylmethylhydroxypyridine malate. Material and methods. The lipid-lowering effect of the combined use of the drugs was tested in experiments using outbred male rats with dyslipidemia caused by the detergent Tween 80. The test substances were injected as a 2% starch gel suspension into the stomach through a probe for 6 days. Results. It was shown that the combined use of atorvastatin and ethylmethylhydroxypyridine malate could significantly lower the dose of atorvastatin, without substantially reducing its lipid-lowering activity. Conclusion. The findings suggest that a pharmaceutical composition with low-dose statins, which has a marked lipid-lowering effect, can be designed.

Full Text

Restricted Access

About the authors

Natalia Dmitrievna Bunyatyan

I.M. Sechenov First Moscow State Medical University (Sechenov University); Research Center for Examination of Medical Products, Ministry of Health of Russia

Email: ndbun@mail.ru
Chief analyst of the Center for clinical pharmacology of the Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP); Head of the Department of pharmaceutical technology and pharmacology, Institute of Pharmacy named after A.P.Nelyubin of Sechenov University, Doctor of Pharmaceutical Sciences, Professor.

Anastasia Evgen'evna Kozlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: kozlovaov2007@yandex.ru
Student of the Institute of Pharmacy named after A.P.Nelyubin

Vladimir Pavlovich Balashov

N.P. Ogarev National Research Mordovia State University

Email: bvp63@yandex.ru
Head of the Department of Cytology, Histology, Embryology Medical Institute

Alexey Vladimirovich Balashov

N.P. Ogarev National Research Mordovia State University

Email: alexeiiiiiii1985@yandex.ru
Associate Professor of the Department of Cytology, Histology, Embryology of the Medical Institute NRMordSU

Ruslan Evgenievich Kazakov

Research Center for Examination of Medical Products, Ministry of Health of Russia

Email: kazakov@expmed.ru
Head of the Department of Personalized Medicine and Clinical Pharmacogenetics of the Center for Clinical Pharmacology SCEEMP.

Aleksey Borisovich Prokofyev

Research Center for Examination of Medical Products, Ministry of Health of Russia

Email: prokofiev@expmed.ru
Director of the Center for Clinical Pharmacology SCEEMP, Doctor of Medical Sciences, Professor.

References

  1. Семенова А.Е., Сергиенко И.В. Фармакологические аспекты терапии статинами. Атеросклероз и дислипидемии. 2013; 2 (11): 4-18.
  2. Бубнова М.Г. Нежелательные эффекты терапии статинами. CARDIOCOMATIKA. 2019; 10 (1): 51-611.
  3. Драпкина О.М., Чернова Е.М., Корнеева О.Н. Статины и миопатия: молекулярные механизмы. Рациональная фармакотерапия в кардиологии. 2012; 8 (3): 469-73.
  4. Catapano A. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart J. 2016; 37 (39): 2999-3058.
  5. Gupta A., Thompson D., Whitehouse A. et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017. doi: 10.1016/S0140-6736(17)31075-9.
  6. Сергиенко И.В., Зубарева М.Ю., Горнякова Н.Б. и др. Эффективность, безопасность и переносимость длительной терапии розувастатином и его фиксированной комбинации с лизиноприлом и амлодипином у больных высокого и очень высокого сердечно-сосудистого риска по результатам наблюдательного исследования АНИЧКОВ. Атеросклероз и дислипидемии. 2019; 2: 22-32.
  7. Оковитый С.В., Заплутанов В. А., Смолина А.Н. Антиоксиданты в современной клинической практике. Клиническая медицина. 2012; 6: 63-7.
  8. Горошко О.А., Кукес В.Г., Прокофьев А.Б. и др. Клинико-фармакологические аспекты применения антиоксидантных лекарственных средств. Международный журнал прикладных и фундаментальных исследований. 2016; 4: 905-12.
  9. Kukes V.G., Parfenova O.K., Romanov B.K. et al. The mechanism of action of ethoxidol on oxidative stress indicesin heart failure and hypotension. Sovremennye tehnologii v medicine. 2020; 12 (2): 67-73. doi: 10.17691/stm 2020.12.2.08
  10. Кукес В.Г., Прокофьев А.Б., Горошко О.А. и др. Влияние этилметилгидроксипиридина малата на напряжение кислорода в крови у пациентов с хронической сердечной недостаточностью. Лекарственные средства и рациональная фармакотерапия. 2013; 3: 18-22.
  11. Кукес В.Г., Горбач Т.В., Ромащенко О.В., Румбешт В.В. Энергосберегающая активность антиоксиданта этоксидола при моделировании ишемии миокарда. Лекарственные препараты и рациональная фармакотерапия. 2014; 1: 16-9.
  12. Логинова В.М., Тузиков Ф.В, Тузикова Н.А. и др. Влияние аторвастатина на липиды сыворотки крови при экспериментальной липемии. Бюллетень СО РАМН. 2011; 31 (2): 133-7.
  13. Goncharova N.V., Khrapova M.V., Pupyshev A.B. et al. Hypolipidemic Effect of Mannan in Mice with Acute Lipemia induced by Poloxammer 407. Bulletin of Experimental Biology and Medicine. 2016; 162 (1): 18-22.
  14. Миронов А.Н., Бунатян Н.Д. и др. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012; 944.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Russkiy Vrach Publishing House